Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
- Autores
- Acuña, Leonardo; Corbalan, Natalia Soledad; Raisman Vozari, Rita
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The World Health Organization has predicted that neurodegenerative diseasesaffecting the motor function will become the second most prevalent cause ofdeath in the next 20 years. New therapies can result from three main sources:synthetic compounds, natural products, and existing drugs. Parkinson?s disease (PD) is a common neurodegenerative disease affecting 1?3% of the adult population over 50 years of age worldwide. It is initially characterized by the death of dopaminergic neurons in the substantia nigra pars compact and later by the widespread loss of nondopaminergic neurons, including those in the cortex (Goedert et al., 2013). Inflammation is the main underlying cause in most, if not all, neurodegenerative diseases, playing a protective role in their initial acute phases, but a pernicious one in their later chronic phases. Increasing evidence has disclosed that microglia-mediated neuroinflammation is crucial for PD progression (Hirsch and Hunot, 2009). Another neuropathological hallmark of PD is the presence of Lewy bodies, which are primarily composed of α-synuclein (α-Syn) aggregates (Goedert et al., 2013). In recent years, important studies on the role of α-Syn in PD have been conducted. The α-Syn aggregation in the central nervous system is a pathological process of fundamental importance in the development and progression of PD. Aggregates of α-Syn, in oligomeric and fibril forms, are thought to be capable of causing neurodegeneration either by directly damaging neurons or by activating microglia to produce neuroinflammatory mediators, which are neurotoxic (Hirsch and Hunot, 2009). Due to the consequent neuronal damage, an aggregation and release process of endogenous α-Syn occurs, triggering microglial activation and leading to neuroinflammation (Sanchez-Guajardo et al., 2015). In this way, α-Syn aggregates generate a vicious circle of neuroinflammation and neuronal death in PD. The interaction between these two players, α-Syn aggregates and microglial cells, is thus believed to be strongly implicated in the inflammatory process that accompanies PD progression. However, the molecular mechanisms that underlie α-Syn-induced microglia activation are not well understood.
Fil: Acuña, Leonardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; Argentina
Fil: Corbalan, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina. Universidad Nacional de Salta; Argentina
Fil: Raisman Vozari, Rita. Centre de Recherche de I'Institut du Cerveau et de la Moelle Epinière; Francia. Sorbonne University; Francia. Inserm; Francia - Materia
-
Inflammation
Drug repurposing
Rifampicin quinone - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/120529
Ver los metadatos del registro completo
id |
CONICETDig_cfb4ac468d4d809a9f2e7acc26141e2d |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/120529 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synucleinAcuña, LeonardoCorbalan, Natalia SoledadRaisman Vozari, RitaInflammationDrug repurposingRifampicin quinonehttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1The World Health Organization has predicted that neurodegenerative diseasesaffecting the motor function will become the second most prevalent cause ofdeath in the next 20 years. New therapies can result from three main sources:synthetic compounds, natural products, and existing drugs. Parkinson?s disease (PD) is a common neurodegenerative disease affecting 1?3% of the adult population over 50 years of age worldwide. It is initially characterized by the death of dopaminergic neurons in the substantia nigra pars compact and later by the widespread loss of nondopaminergic neurons, including those in the cortex (Goedert et al., 2013). Inflammation is the main underlying cause in most, if not all, neurodegenerative diseases, playing a protective role in their initial acute phases, but a pernicious one in their later chronic phases. Increasing evidence has disclosed that microglia-mediated neuroinflammation is crucial for PD progression (Hirsch and Hunot, 2009). Another neuropathological hallmark of PD is the presence of Lewy bodies, which are primarily composed of α-synuclein (α-Syn) aggregates (Goedert et al., 2013). In recent years, important studies on the role of α-Syn in PD have been conducted. The α-Syn aggregation in the central nervous system is a pathological process of fundamental importance in the development and progression of PD. Aggregates of α-Syn, in oligomeric and fibril forms, are thought to be capable of causing neurodegeneration either by directly damaging neurons or by activating microglia to produce neuroinflammatory mediators, which are neurotoxic (Hirsch and Hunot, 2009). Due to the consequent neuronal damage, an aggregation and release process of endogenous α-Syn occurs, triggering microglial activation and leading to neuroinflammation (Sanchez-Guajardo et al., 2015). In this way, α-Syn aggregates generate a vicious circle of neuroinflammation and neuronal death in PD. The interaction between these two players, α-Syn aggregates and microglial cells, is thus believed to be strongly implicated in the inflammatory process that accompanies PD progression. However, the molecular mechanisms that underlie α-Syn-induced microglia activation are not well understood.Fil: Acuña, Leonardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; ArgentinaFil: Corbalan, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina. Universidad Nacional de Salta; ArgentinaFil: Raisman Vozari, Rita. Centre de Recherche de I'Institut du Cerveau et de la Moelle Epinière; Francia. Sorbonne University; Francia. Inserm; FranciaShenyang Editorial Dept Neural Regeneration Res2019-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/120529Acuña, Leonardo; Corbalan, Natalia Soledad; Raisman Vozari, Rita; Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein; Shenyang Editorial Dept Neural Regeneration Res; Neural Regeneration Research; 15; 8; 12-2019; 1473-14741673-5374CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4103/1673-5374.274336info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059564/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:16:39Zoai:ri.conicet.gov.ar:11336/120529instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:16:39.397CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein |
title |
Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein |
spellingShingle |
Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein Acuña, Leonardo Inflammation Drug repurposing Rifampicin quinone |
title_short |
Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein |
title_full |
Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein |
title_fullStr |
Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein |
title_full_unstemmed |
Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein |
title_sort |
Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein |
dc.creator.none.fl_str_mv |
Acuña, Leonardo Corbalan, Natalia Soledad Raisman Vozari, Rita |
author |
Acuña, Leonardo |
author_facet |
Acuña, Leonardo Corbalan, Natalia Soledad Raisman Vozari, Rita |
author_role |
author |
author2 |
Corbalan, Natalia Soledad Raisman Vozari, Rita |
author2_role |
author author |
dc.subject.none.fl_str_mv |
Inflammation Drug repurposing Rifampicin quinone |
topic |
Inflammation Drug repurposing Rifampicin quinone |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
The World Health Organization has predicted that neurodegenerative diseasesaffecting the motor function will become the second most prevalent cause ofdeath in the next 20 years. New therapies can result from three main sources:synthetic compounds, natural products, and existing drugs. Parkinson?s disease (PD) is a common neurodegenerative disease affecting 1?3% of the adult population over 50 years of age worldwide. It is initially characterized by the death of dopaminergic neurons in the substantia nigra pars compact and later by the widespread loss of nondopaminergic neurons, including those in the cortex (Goedert et al., 2013). Inflammation is the main underlying cause in most, if not all, neurodegenerative diseases, playing a protective role in their initial acute phases, but a pernicious one in their later chronic phases. Increasing evidence has disclosed that microglia-mediated neuroinflammation is crucial for PD progression (Hirsch and Hunot, 2009). Another neuropathological hallmark of PD is the presence of Lewy bodies, which are primarily composed of α-synuclein (α-Syn) aggregates (Goedert et al., 2013). In recent years, important studies on the role of α-Syn in PD have been conducted. The α-Syn aggregation in the central nervous system is a pathological process of fundamental importance in the development and progression of PD. Aggregates of α-Syn, in oligomeric and fibril forms, are thought to be capable of causing neurodegeneration either by directly damaging neurons or by activating microglia to produce neuroinflammatory mediators, which are neurotoxic (Hirsch and Hunot, 2009). Due to the consequent neuronal damage, an aggregation and release process of endogenous α-Syn occurs, triggering microglial activation and leading to neuroinflammation (Sanchez-Guajardo et al., 2015). In this way, α-Syn aggregates generate a vicious circle of neuroinflammation and neuronal death in PD. The interaction between these two players, α-Syn aggregates and microglial cells, is thus believed to be strongly implicated in the inflammatory process that accompanies PD progression. However, the molecular mechanisms that underlie α-Syn-induced microglia activation are not well understood. Fil: Acuña, Leonardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; Argentina Fil: Corbalan, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina. Universidad Nacional de Salta; Argentina Fil: Raisman Vozari, Rita. Centre de Recherche de I'Institut du Cerveau et de la Moelle Epinière; Francia. Sorbonne University; Francia. Inserm; Francia |
description |
The World Health Organization has predicted that neurodegenerative diseasesaffecting the motor function will become the second most prevalent cause ofdeath in the next 20 years. New therapies can result from three main sources:synthetic compounds, natural products, and existing drugs. Parkinson?s disease (PD) is a common neurodegenerative disease affecting 1?3% of the adult population over 50 years of age worldwide. It is initially characterized by the death of dopaminergic neurons in the substantia nigra pars compact and later by the widespread loss of nondopaminergic neurons, including those in the cortex (Goedert et al., 2013). Inflammation is the main underlying cause in most, if not all, neurodegenerative diseases, playing a protective role in their initial acute phases, but a pernicious one in their later chronic phases. Increasing evidence has disclosed that microglia-mediated neuroinflammation is crucial for PD progression (Hirsch and Hunot, 2009). Another neuropathological hallmark of PD is the presence of Lewy bodies, which are primarily composed of α-synuclein (α-Syn) aggregates (Goedert et al., 2013). In recent years, important studies on the role of α-Syn in PD have been conducted. The α-Syn aggregation in the central nervous system is a pathological process of fundamental importance in the development and progression of PD. Aggregates of α-Syn, in oligomeric and fibril forms, are thought to be capable of causing neurodegeneration either by directly damaging neurons or by activating microglia to produce neuroinflammatory mediators, which are neurotoxic (Hirsch and Hunot, 2009). Due to the consequent neuronal damage, an aggregation and release process of endogenous α-Syn occurs, triggering microglial activation and leading to neuroinflammation (Sanchez-Guajardo et al., 2015). In this way, α-Syn aggregates generate a vicious circle of neuroinflammation and neuronal death in PD. The interaction between these two players, α-Syn aggregates and microglial cells, is thus believed to be strongly implicated in the inflammatory process that accompanies PD progression. However, the molecular mechanisms that underlie α-Syn-induced microglia activation are not well understood. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-12 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/120529 Acuña, Leonardo; Corbalan, Natalia Soledad; Raisman Vozari, Rita; Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein; Shenyang Editorial Dept Neural Regeneration Res; Neural Regeneration Research; 15; 8; 12-2019; 1473-1474 1673-5374 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/120529 |
identifier_str_mv |
Acuña, Leonardo; Corbalan, Natalia Soledad; Raisman Vozari, Rita; Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein; Shenyang Editorial Dept Neural Regeneration Res; Neural Regeneration Research; 15; 8; 12-2019; 1473-1474 1673-5374 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.4103/1673-5374.274336 info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059564/ |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Shenyang Editorial Dept Neural Regeneration Res |
publisher.none.fl_str_mv |
Shenyang Editorial Dept Neural Regeneration Res |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842980907614470144 |
score |
12.993085 |